ERBB2 and non-small cell lung carcinoma: Trastuzumab is approved for the treatment of breast, gastric and gastroesophageal junction cancer by the US Federal Drugs Administration (FDA), and there are mounting anecdotal reports of responses to HER2-targeted agents in patients with NSCLC [29–33] and cancer of the salivary duct [34–38].